EP 2473186 A1 20120711 - BISPECIFIC IMMUNOCYTOKINE DOCK-AND-LOCK (DNL) COMPLEXES AND THERAPEUTIC USE THEREOF
Title (en)
BISPECIFIC IMMUNOCYTOKINE DOCK-AND-LOCK (DNL) COMPLEXES AND THERAPEUTIC USE THEREOF
Title (de)
BISPEZIFISCHE IMMUNOZYTOKIN-DOCK-AND-LOCK-KOMPLEXE UND THERAPEUTISCHE VERWENDUNG DAVON
Title (fr)
COMPLEXES DNL (DOCK-AND-LOCK) À BASE D'IMMUNOCYTOKINES BISPÉCIFIQUES ET LEURS UTILISATIONS THÉRAPEUTIQUES
Publication
Application
Priority
- US 23842409 P 20090831
- US 64414609 A 20091222
- US 73178110 A 20100325
- US 75264910 A 20100401
- US 75414010 A 20100405
- US 75474010 A 20100406
- US 2010046889 W 20100827
Abstract (en)
[origin: WO2011025904A1] The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFNa2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.
IPC 8 full level
A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 14/56 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC (source: EP)
A61P 1/04 (2017.12); A61P 3/10 (2017.12); A61P 7/06 (2017.12); A61P 9/00 (2017.12); A61P 9/14 (2017.12); A61P 11/00 (2017.12); A61P 13/12 (2017.12); A61P 17/00 (2017.12); A61P 17/06 (2017.12); A61P 19/02 (2017.12); A61P 21/02 (2017.12); A61P 21/04 (2017.12); A61P 25/00 (2017.12); A61P 25/14 (2017.12); A61P 35/00 (2017.12); A61P 35/02 (2017.12); A61P 37/00 (2017.12); A61P 37/02 (2017.12); C07K 14/52 (2013.01); C07K 16/249 (2013.01); C07K 16/2833 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2319/30 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
DOCDB simple family (publication)
WO 2011025904 A1 20110303; AU 2010286642 A1 20120216; AU 2010286642 B2 20160310; CA 2772572 A1 20110303; CN 102481348 A 20120530; EP 2473186 A1 20120711; EP 2473186 A4 20130710; IN 1331DEN2012 A 20150605; JP 2013503184 A 20130131; JP 2015157832 A 20150903; JP 5740772 B2 20150701; JP 5999217 B2 20160928
DOCDB simple family (application)
US 2010046889 W 20100827; AU 2010286642 A 20100827; CA 2772572 A 20100827; CN 201080038548 A 20100827; EP 10812633 A 20100827; IN 1331DEN2012 A 20120213; JP 2012527002 A 20100827; JP 2015080993 A 20150410